Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Eric S. Schafer, Rachel E. Rau, Stacey L. Berg, Xiaowei Liu, Charles G. Minard, Alexander J.R. Bishop, J. Carolina Romero, M. John Hicks, Marvin D. Nelson, Stephan Voss, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Susan M. Blaney

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Purpose: We conducted a phase 1/2 trial of the poly(ADP-ribose) polymerase 1/2 inhibitor talazoparib in combination with low-dose temozolomide (TMZ) to determine the dose-limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777). Methods: Talazoparib (400-600 µg/m2/dose, maximum daily dose 800-1000 µg) was administered q.d. or b.i.d. orally on day 1 followed by q.d. dosing concomitant with q.d. dosing of oral TMZ (20-55 mg/m2/day) on days 2 to 6, every 28 days. Results: Forty patients, aged 4 to 25 years, were enrolled. Talazoparib was increased to 600 µg/m2/dose b.i.d. on day 1, and q.d. thereafter, with 20 mg/m2/day of TMZ, without DLTs. TMZ was subsequently increased, during which dose-limiting neutropenia and thrombocytopenia occurred in two of three subjects at 55 mg/m2/day, two of six subjects at 40 mg/m2/day, and one of six subjects at 30 mg/m2/day. During dose-finding, two of five EWS and four of 25 non-EWS subjects experienced prolonged stable disease (SD), and one subject with malignant glioma experienced a partial response. In phase 2, 0 of 10 EWS subjects experienced an objective response; two experienced prolonged SD. Conclusions: Talazoparib and low-dose TMZ are tolerated in children with recurrent/refractory solid tumors. Reversible neutropenia and thrombocytopenia were dose limiting. The RP2D is talazoparib 600 µg/m2 b.i.d. on day 1 followed by 600 µg/m2 q.d. on days 2 to 6 (daily maximum 1000 µg) in combination with temozolomide 30 mg/m2/day on days 2 to 6. Antitumor activity was not observed in EWS, and limited antitumor activity was observed in central nervous system tumors.

Original languageEnglish (US)
Article numbere28073
JournalPediatric Blood and Cancer
Volume67
Issue number2
DOIs
StatePublished - Feb 1 2020

Bibliographical note

Funding Information:
This research was supported by the NCI of the NIH under award number UM1 CA228823, A Conquer Cancer Foundation of ASCO Career Development Award (ESS), NCI award 1R01CA152063 and CPRIT award RP150445 (AJRB), CPRIT Training Fellowship RP140105 (JCR), NCI award P30 CA015083 (JMR), Cookies for Kids’ Cancer Foundation, and the Children's Oncology Group Foundation. BioMarin Pharmaceutical, Inc., Medivation, Inc., and Pfizer provided talazoparib as well as support for the talazoparib PK assay throughout the study.

Keywords

  • PARP inhibitor
  • pharmacokinetics
  • phase 1
  • talazoparib
  • temozolomide

Fingerprint Dive into the research topics of 'Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)'. Together they form a unique fingerprint.

Cite this